Literature DB >> 10839554

Combination antihypertensive drugs: recommendations for use.

N S Skolnik1, J D Beck, M Clark.   

Abstract

The recommendation for first-line therapy for hypertension remains a beta blocker or diuretic given in a low dosage. A target blood pressure of less than 140/90 mm Hg is achieved in about 50 percent of patients treated with monotherapy; two or more agents from different pharmacologic classes are often needed to achieve adequate blood pressure control. Single-dose combination antihypertension therapy is an important option that combines efficacy of blood pressure reduction and a low side effect profile with convenient once-daily dosing to enhance compliance. Combination antihypertensives include combined agents from the following pharmacologic classes: diuretics and potassium-sparing diuretics, beta blockers and diuretics, angiotensin-converting enzyme (ACE) inhibitors and diuretics, angiotensin-II antagonists and diuretics, and calcium channel blockers and ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839554

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

Review 1.  Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Authors:  Richard B R Muijsers; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  [Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension].

Authors:  F Antoñanzas; M Velasco; I Abbas; C Pontes; J Delgadillo; M Terán
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

Review 3.  Dispelling the myth of "aggressive" antihypertensive therapy.

Authors:  Elizabeth O Ofili
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

Review 4.  Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring.

Authors:  Sverre E Kjeldsen; Tonje A Aksnes; Luis M Ruilope
Journal:  Drugs R D       Date:  2014-06

5.  Chemical stability and interactions in a new antihypertensive mixture containing indapamide and dihydralazine using FT-IR, HPLC and LC-MS methods.

Authors:  Anna Gumieniczek; Justyna Galeza; Anna Berecka; Tomasz Mroczek; Krzysztof Wojtanowski; Katarzyna Lipska; Joanna Skarbek
Journal:  RSC Adv       Date:  2018-10-23       Impact factor: 4.036

Review 6.  Emerging insights in the first-step use of antihypertensive combination therapy.

Authors:  Keith Norris; Joel M Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-12       Impact factor: 3.738

Review 7.  The concept of crosstalk-directed embryological target mining and its application to essential hypertension treatment failures.

Authors:  Alan Alper Sag; Oguzhan Sal; Yagmur Kilic; Emine Meltem Onal; Mehmet Kanbay
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-02-21       Impact factor: 3.738

Review 8.  Managing hypertension in African-American patients.

Authors:  Elijah Saunders
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

9.  Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study.

Authors:  Joel M Neutel; David H G Smith; Michael A Weber; Lesley Schofield; Das Purkayastha; Marjorie Gatlin
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

Review 10.  Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.

Authors:  Kalathil K Sureshkumar
Journal:  Vasc Health Risk Manag       Date:  2008
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.